Abstract
The Multinational Association of Supportive Cancer Care (MASCC) score index has been developed to predict a low risk (<5 %) of complications in patients with febrile neutropenia (FN). In our original study, a score ≤21 identified low-risk patients with a positive predictive value of 91 %, specificity of 68 %, and sensitivity of 71 %; these patients had <5 % of severe complications and 16% died (4 out of 243). More recent validations of the MASCC score have confirmed a somewhat higher frequency of complications (12–18 %), but still a low mortality of 2–3 %.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.
Pun Hui E, Leung KS, Poon T, et al. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer. 2011;19:1625-1635.
Klastersky J, Ameye L, Maertens, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51-S59.
Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactamaminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003;326:1111.
Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999;314:312-318.
Rolston KV, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS. Oral moxifloxacin for outpatients treatment of low-risk, febrile neutropenic patients. Support Care Cancer. 2010;18:89-94.
Kern WV, Marchetti O, Drgoina L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy–EORTC infectious diseases group trial XV. J Clin Oncol. 2013;31:1149-1156.
Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24:4129-4134.
Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic-therapy for low-risk cancer patients with fever and neutropenia-a pilot-study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994;12:107-114.
Freifeld A, Marchigiani D, Walsh T, et al. A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999;341:305-311.
Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinoloneresistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38:681-687.
Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24:111-118.
Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61:721-728.
Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infection: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis. 2005;41:923-929.
Rubenstein EB, Rolston K VI. Risk-adjusted management of the febrile neutropenic cancer patient. In: Rolston RV, Rubinstein EB, eds Textbook of Febrile Neutropenia. London, UK: Martin Dunitz, Ltd;2001:167-188.
Innes HE, Smith DB, O’Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patients intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study. Br J Cancer. 2003;89:43-49.
Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer. 2008;16:485-491.
Cherif H, Johansson E, Björkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica. 2006;91:215-222.
Brack E, Bodmer N, Simon A, et al. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN Study. Pediatr Blood Cancer. 2012;59:423-430.
Carstensen M, Sørensen JB. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol. 2008;6:199-208.
Teuffel O, Ethier MC, Alibhai SM, Beyene J, Sung L. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol. 2011;22:2358-2365.
Teuffel O, Amir E, Alibhai S, Beyene J, Sung L. Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. Br J Cancer. 2011;104:1377-1383.
Elting L, Lu C, Escalante C, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008;26:606-611.
Sebban C, Dussart S, Fuhrmann C, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer. 2008;16:1017-1023.
Lathia N, Isogai PK, Walker SE, et al. Eliciting patients’ preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment. Support Care Cancer. 2012;21:245-251.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer Healthcare
About this chapter
Cite this chapter
Klastersky, J.A. (2014). Management of the Low-Risk Patients. In: Febrile Neutropenia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-70-2_4
Download citation
DOI: https://doi.org/10.1007/978-1-907673-70-2_4
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-907673-69-6
Online ISBN: 978-1-907673-70-2
eBook Packages: MedicineMedicine (R0)